Zimmer Biomet (ZBH) appointed Jonathan Vigdorchik as Chief Science, Technology and Medical Affairs Officer, effective April 14. In this role, Vigdorchik will oversee the strategy, delivery, and management of the company’s global end-to-end technology portfolio, including AI, robotics, smart implants and data. He will also oversee Zimmer Biomet’s Medical Education strategy and Global Advisory Board. Vigdorchik previously served as Zimmer Biomet’s Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants. He is a board-certified, fellowship-trained orthopedic surgeon at Hospital for Special Surgery in New York City.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet’s RibFix Titan Study: What Chest Wall Data Could Mean for ZBH Investors
- Zimmer Biomet’s Mymobility Study: Fresh Clinical Data on a Digital Edge in Joint Replacement
- Super Micro downgraded, MongoDB upgraded: Wall Street’s top analyst calls
- Zimmer Biomet downgraded to Neutral from Buy at BTIG
- Zimmer Biomet’s New Knee Implant Study Builds a Quiet Catalyst for Long-Term Growth